DERM - Dermira Inc Stock Price, Fair Value and News

3.54USD+0.06 (+1.72%)Delayed as of 22 Apr 2024, 12:40 pm ET

Market Summary

USD3.54+0.06

Delayedas of 22 Apr 2024, 12:40 pm

1.72%

DERM Alerts

3 major insider buys recently.

DERM Stock Price

View Fullscreen

DERM RSI Chart

DERM Valuation

Market Cap

63.4M

Price/Earnings (Trailing)

-16.47

Price/Sales (Trailing)

0.8

EV/EBITDA

-26.2

Price/Free Cashflow

12.11

DERM Price/Sales (Trailing)

DERM Profitability

Operating Margin

66.33%

EBT Margin

-4.59%

Return on Equity

-18.93%

Return on Assets

-5.01%

Free Cashflow Yield

8.26%

DERM Fundamentals

DERM Revenue

Revenue (TTM)

79.2M

Rev. Growth (Yr)

-4.44%

Rev. Growth (Qtr)

-55.83%

DERM Earnings

Earnings (TTM)

-3.9M

Earnings Growth (Yr)

79.86%

Earnings Growth (Qtr)

-112.76%

Breaking Down DERM Revenue

52 Week Range

1.023.58

(Low)(High)

Last 7 days

-21.9%

Last 30 days

-10.2%

Last 90 days

-31.9%

Trailing 12 Months

114.0%

How does DERM drawdown profile look like?

DERM Financial Health

Current Ratio

1.35

Debt/Equity

0.72

Debt/Cashflow

0.36

DERM Investor Care

Shares Dilution (1Y)

4.00%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	62.6M	61.5M	79.9M	79.2M
2022	75.7M	78.7M	75.2M	73.7M
2021	49.2M	53.8M	58.5M	63.1M
2020	0	0	0	44.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dermira Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	rosenwald lindsay a md	bought	30,400	3.04	10,000	-
Mar 22, 2024	smith justin adam	bought	104,100	3.47	30,000	-
Mar 22, 2024	maraoui claude	bought	34,790	3.479	10,000	president & ceo
Mar 22, 2024	rosenwald lindsay a md	bought	68,000	3.4	20,000	-
Feb 22, 2024	benesch joseph	sold	-9,187	3.75	-2,450	interim cfo
Nov 28, 2023	paley jeffrey	sold	-9,108	5.22	-1,745	-
Nov 08, 2023	paley jeffrey	sold	-958	3.76	-255	-
Nov 07, 2023	paley jeffrey	sold	-7,812	3.48	-2,245	-
Oct 13, 2023	smith justin adam	bought	98,340	2.98	33,000	-
Oct 06, 2023	paley jeffrey	bought	44,700	2.98	15,000	-

Which funds bought or sold DERM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	78.14	546,513	745,621	-%
Mar 04, 2024	TUCKER ASSET MANAGEMENT LLC	new	-	14,976	14,976	-%
Feb 26, 2024	Virtu Financial LLC	new	-	153,000	153,000	0.01%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	159,834	159,834	-%
Feb 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-955,337	-	-%
Feb 14, 2024	Cubist Systematic Strategies, LLC	new	-	135,003	135,003	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	65,416	65,416	-%
Feb 14, 2024	Royal Bank of Canada	added	93.33	-	-	-%
Feb 14, 2024	LAZARD ASSET MANAGEMENT LLC	new	-	2,000	2,000	-%
Feb 14, 2024	TANG CAPITAL MANAGEMENT LLC	sold off	-100	-1,578,510	-	-%

Are Funds Buying or Selling DERM?

Are funds buying DERM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DERM

No. of Funds

DERM Alerts

3 major insider buys recently.

Unveiling Dermira Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 29, 2022	b. riley financial, inc.	4.9%	864,695	SC 13G/A
Aug 17, 2022	fortress biotech, inc.	56.9%	10,010,467	SC 13G
Feb 11, 2022	b. riley financial, inc.	5.2%	864,695	SC 13G

Recent SEC filings of Dermira Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to Dermira Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	356.3B	85.2B	-5.03%	-9.57%	10.14	4.18	6.46%	95.94%
MRK	318.7B	60.1B	1.61%	10.23%	873.24	5.3	1.40%	-97.49%
PFE	146.8B	46.5B	-6.17%	-34.78%	-105.7	3.15	42.59%	-114.62%
AMGN	144.1B	28.2B	-1.51%	10.46%	21.46	5.11	7.09%	2.52%
GILD	83.2B	27.1B	-9.77%	-21.18%	14.68	3.07	-0.60%	23.36%
TEVA	14.4B	15.8B	-4.60%	54.01%	-25	0.91	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	-1.63%	-14.16%	-328.65	0.9	4.58%	90.97%
ALKS	4.0B	1.7B	-13.93%	-17.76%	11.2	2.4	49.61%	324.78%
BHC	3.2B	8.8B	-9.38%	13.00%	-5.36	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-9.13%	-7.04%	13.99	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-12.63%	-26.38%	-3.8	1.8	24.65%	80.36%
TXMD	21.6M	1.3M	-20.43%	-49.32%	-2.1	16.56	-98.14%	-109.18%
ACRX	16.6M	-	-10.09%	36.11%	-0.9	0.22	2882.68%	-138.52%
AGRX	2.6M	19.6M	-34.48%	-94.22%	-0.18	0.13	80.00%	43.08%
ACOR	546.5K	117.6M	-96.48%	-95.45%	0	0	-0.79%	-283.60%

Dermira Inc News

Latest updates

Dermira Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-55.8%	15,257,000	34,539,000	17,172,000	12,213,000	15,966,000	16,116,000	18,291,000	23,296,000	17,517,000	19,610,000	15,288,000	10,719,000	10,083,000	9,447,000
Cost Of Revenue	-6.4%	6,015,000	6,429,000	7,767,000	6,449,000	7,718,000	7,221,000	7,633,000	8,203,000	9,525,000	11,167,000	7,484,000	3,908,000	-	3,379,000
Costs and Expenses	0.4%	17,361,000	17,294,000	24,825,000	21,774,000	25,961,000	25,608,000	25,433,000	24,184,000	26,574,000	32,256,000	29,051,000	10,134,000	-	9,208,000
S&GA Expenses	14.0%	9,841,000	8,636,000	12,141,000	13,292,000	13,987,000	15,575,000	15,191,000	14,715,000	15,057,000	10,755,000	7,795,000	6,226,000	-	5,829,000
R&D Expenses	-32.5%	1,505,000	2,229,000	1,774,000	2,033,000	4,256,000	2,812,000	2,609,000	1,266,000	-	718,000	29,000	-	-	-
EBITDA Margin	80.4%	-0.02	-0.12	-0.60	-0.58	-0.37	-0.36	-0.38	-0.49	-0.56	0.13	0.15	0.16	0.18	-
Interest Expenses	-91.0%	24,000	268,000	756,000	650,000	617,000	559,000	454,000	389,000	4,098,000	1,373,000	1,342,000	221,000	-	-
Income Taxes	32.6%	126,000	95,000	78,000	7,000	13,000	10,000	-64,000	104,000	8,335,000	-3,375,000	-3,422,000	96,000	-	23,000
Earnings Before Taxes	-111.9%	-2,017,000	16,884,000	-8,363,000	-10,136,000	-10,629,000	-10,070,000	-7,592,000	-1,274,000	-13,416,000	-14,021,000	-15,287,000	364,000	-	52,000
EBT Margin	70.1%	-0.05	-0.15	-0.64	-0.61	-0.40	-0.43	-0.46	-0.58	-0.67	0.12	0.13	0.15	0.16	-
Net Income	-112.8%	-2,143,000	16,789,000	-8,363,000	-10,136,000	-10,642,000	-10,080,000	-7,528,000	-1,378,000	-21,751,000	-10,646,000	-11,865,000	268,000	-	29,000
Net Income Margin	68.5%	-0.05	-0.15	-0.64	-0.61	-0.40	-0.54	-0.52	-0.60	-0.70	0.09	0.10	0.11	0.12	-
Free Cashflow	-188.1%	-16,520,000	18,747,000	3,969,000	-956,000	-3,836,000	-7,282,000	-3,300,000	884,000	-3,206,000	7,102,000	-7,438,000	1,361,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	16.6%	77.00	66.00	70.00	96.00	105	108	113	121	97.00	89.00	52.00
Current Assets	26.3%	56.00	45.00	48.00	61.00	78.00	80.00	84.00	90.00	84.00	67.00	35.00
Cash Equivalents	10.9%	27.00	25.00	8.00	17.00	32.00	35.00	38.00	41.00	49.00	22.00	8.00
Inventory	-7.4%	10.00	11.00	12.00	13.00	14.00	15.00	16.00	16.00	10.00	12.00	1.00
Liabilities	16.4%	56.00	49.00	70.00	88.00	88.00	82.00	79.00	79.00	55.00	101	42.00
Current Liabilities	-13.7%	42.00	49.00	68.00	77.00	67.00	61.00	60.00	61.00	52.00	60.00	28.00
Long Term Debt	-	15.00	-	-	10.00	20.00	20.00	15.00	15.00	-	-	-
LT Debt, Current	-	-	-	10.00	10.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	15.00	-	-	10.00	20.00	20.00	15.00	15.00	-	-	-
Shareholder's Equity	17.1%	20.00	17.00	0.00	7.00	17.00	26.00	35.00	41.00	42.00	-	10.00
Retained Earnings	-3.1%	-72.35	-70.21	-87.00	-78.64	-68.50	-57.86	-47.78	-40.25	-38.87	-17.12	5.00
Additional Paid-In Capital	5.8%	93.00	88.00	87.00	86.00	85.00	84.00	83.00	82.00	81.00	5.00	5.00
Shares Outstanding	-1.0%	18.00	18.00	18.00	18.00	18.00	17.00	17.00	17.00	10.00	9.00	9.00
Float	-	-	-	12.00	-	-	-	26.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-188.1%	-16,520	18,747	3,969	-956	-3,836	-7,282	-3,300	884	-3,206	7,102	-7,438	1,361	-	-
Share Based Compensation	-5.2%	529	558	873	646	1,440	1,438	774	773	2,425	8.00	11.00	22.00	-	-
Cashflow From Investing	-	-	-	-	-5,000	-	-	-	-20,000	-1,200	-	-	-	-	-
Cashflow From Financing	275.0%	19,210	-10,978	-13,088	52.00	948	4,031	111	11,366	31,798	11,211	616	9,391	-	-

DERM Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Product revenue, net	$ 59,662	$ 70,995
Other revenue	19,519	2,674
Total revenue	79,181	73,669
Operating expenses
Cost of goods sold - product revenue	26,660	30,775
Research and development	7,541	10,943
Selling, general and administrative	43,910	59,468
Loss on impairment of intangible assets	3,143
Total operating expenses	81,254	101,186
Loss from operations	(2,073)	(27,517)
Other expense (income)
Interest income	(322)	(60)
Interest expense	1,698	2,019
Foreign exchange transaction losses	183	89
Total other expense (income)	1,559	2,048
Loss before income taxes	(3,632)	(29,565)
Income tax expense	221	63
Net Loss	$ (3,853)	$ (29,628)
Net loss per common share:
Basic	$ (0.21)	$ (1.69)
Diluted	$ (0.21)	$ (1.69)
Weighted average number of common shares:
Basic	18,232,422	17,531,274

DERM Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 27,439	$ 32,003
Accounts receivable, net of reserves	15,222	28,208
Inventory	10,206	14,159
Prepaid expenses and other current assets	3,588	3,309
Total current assets	56,455	77,679
Intangible assets, net	20,287	27,197
Operating lease right-of-use asset, net	101	189
Other assets	6	95
Total assets	76,849	105,160
Current liabilities
Accounts payable	18,149	36,570
Due to related party	$ 195	$ 413
Other Liability, Current, Related Party, Type [Extensible Enumeration]	us-gaap:RelatedPartyMember	us-gaap:RelatedPartyMember
Accrued expenses	$ 20,350	$ 19,388
Accrued interest	22	160
Income taxes payable	53	35
Line of credit		2,948
Deferred cash payment, net of discount		4,991
Installment payments - licenses, short-term	3,000	2,244
Operating lease liability, short-term	99	83
Total current liabilities	41,868	66,832
Term loan, net of discount	14,622	19,826
Installment payments - licenses, long-term		1,412
Operating lease liability, long-term	9	108
Total liabilities	56,499	88,178
Commitments and contingencies (Note 14)
Stockholders' equity
Additional paid-in capital	92,703	85,482
Accumulated deficit	(72,355)	(68,502)
Total stockholders' equity	20,350	16,982
Total liabilities and stockholders' equity	76,849	105,160
Common stock
Stockholders' equity
Common stock	1	1
Common Stock Class A
Stockholders' equity
Common stock	$ 1	$ 1

About Dermira Inc

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

CEO	Mr. Claude Maraoui
WEBSITE	https://journeymedicalcorp.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	20

Dermira Inc Frequently Asked Questions

What is the ticker symbol for Dermira Inc? What does DERM stand for in stocks?

DERM is the stock ticker symbol of Dermira Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dermira Inc (DERM)?

As of Fri Apr 19 2024, market cap of Dermira Inc is 63.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DERM stock?

You can check DERM's fair value in chart for subscribers.

What is the fair value of DERM stock?

You can check DERM's fair value in chart for subscribers. The fair value of Dermira Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dermira Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DERM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dermira Inc a good stock to buy?

The fair value guage provides a quick view whether DERM is over valued or under valued. Whether Dermira Inc is cheap or expensive depends on the assumptions which impact Dermira Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DERM.

What is Dermira Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, DERM's PE ratio (Price to Earnings) is -16.47 and Price to Sales (PS) ratio is 0.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DERM PE ratio will change depending on the future growth rate expectations of investors.